

# Ian G Mills

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/166140/ian-g-mills-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

185  
papers

14,116  
citations

48  
h-index

117  
g-index

245  
ext. papers

16,485  
ext. citations

8  
avg, IF

6.04  
L-index

#	Paper	IF	Citations
185	Hyperpolarised C-MRI identifies the emergence of a glycolytic cell population within intermediate-risk human prostate cancer.. <i>Nature Communications</i> , <b>2022</b> , 13, 466	17.4	0
184	CaMKK2 facilitates Golgi-associated vesicle trafficking to sustain cancer cell proliferation. <i>Cell Death and Disease</i> , <b>2021</b> , 12, 1040	9.8	1
183	Transcript analysis of commercial prostate cancer risk stratification panels in hard-to-predict grade group 2-4 prostate cancers. <i>Prostate</i> , <b>2021</b> , 81, 368-376	4.2	1
182	Common genetic and clinical risk factors: association with fatal prostate cancer in the Cohort of Swedish Men. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2021</b> , 24, 845-851	6.2	3
181	IGF-1R nuclear import and recruitment to chromatin involves both alpha and beta subunits. <i>Discover Oncology</i> , <b>2021</b> , 12, 13		0
180	Vascular normalisation as the stepping stone into tumour microenvironment transformation. <i>British Journal of Cancer</i> , <b>2021</b> , 125, 324-336	8.7	11
179	Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer. <i>British Journal of Cancer</i> , <b>2021</b> , 125, 534-546	8.7	1
178	A Systematic Review of Prostate Cancer Heterogeneity: Understanding the Clonal Ancestry of Multifocal Disease. <i>European Urology Oncology</i> , <b>2021</b> , 4, 358-369	6.7	4
177	African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer. <i>International Journal of Cancer</i> , <b>2021</b> , 148, 99-105	7.5	7
176	Derivation and Application of Molecular Signatures to Prostate Cancer: Opportunities and Challenges. <i>Cancers</i> , <b>2021</b> , 13,	6.6	9
175	O-GlcNAc Transferase - An Auxiliary Factor or a Full-blown Oncogene?. <i>Molecular Cancer Research</i> , <b>2021</b> , 19, 555-564	6.6	8
174	Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2021</b> , 24, 532-541	6.2	3
173	Common genetic and clinical risk factors: Association with fatal prostate cancer in the Cohort of Swedish Men.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 65-65	2.2	
172	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. <i>Nature Communications</i> , <b>2021</b> , 12, 1236	17.4	14
171	Modulating the unfolded protein response with ONC201 to impact on radiation response in prostate cancer cells. <i>Scientific Reports</i> , <b>2021</b> , 11, 4252	4.9	4
170	ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer. <i>Cancer Research</i> , <b>2021</b> , 81, 1704-1718	10.1	16
169	A feedback loop between the androgen receptor and 6-phosphogluconate dehydrogenase (6PGD) drives prostate cancer growth. <i>ELife</i> , <b>2021</b> , 10,	8.9	6

168	The Interplay Between Prostate Cancer Genomics, Metabolism, and the Epigenome: Perspectives and Future Prospects. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 704353	5.3	3
167	Inhibition of CDK9 activity compromises global splicing in prostate cancer cells. <i>RNA Biology</i> , <b>2021</b> , 1-8	4.8	4
166	Ductal adenocarcinoma of the prostate: A systematic review and meta-analysis of incidence, presentation, prognosis, and management.. <i>BJUI Compass</i> , <b>2021</b> , 2, 13-23	0.9	2
165	Independence of HIF1a and androgen signaling pathways in prostate cancer. <i>BMC Cancer</i> , <b>2020</b> , 20, 469	4.8	8
164	The effect of sample size on polygenic hazard models for prostate cancer. <i>European Journal of Human Genetics</i> , <b>2020</b> , 28, 1467-1475	5.3	5
163	Propagation of human prostate tissue from induced pluripotent stem cells. <i>Stem Cells Translational Medicine</i> , <b>2020</b> , 9, 734-745	6.9	13
162	Sjögren syndrome/scleroderma autoantigen 1 is a direct Tankyrase binding partner in cancer cells. <i>Communications Biology</i> , <b>2020</b> , 3, 123	6.7	3
161	A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2020</b> , 29, 1731-1738	4	14
160	Inhibition of O-GlcNAc Transferase Renders Prostate Cancer Cells Dependent on CDK9. <i>Molecular Cancer Research</i> , <b>2020</b> , 18, 1512-1521	6.6	17
159	Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model. <i>British Journal of Cancer</i> , <b>2020</b> , 123, 1089-1100	8.7	30
158	Detailed Molecular and Immune Marker Profiling of Archival Prostate Cancer Samples Reveals an Inverse Association between TMPRSS2:ERG Fusion Status and Immune Cell Infiltration. <i>Journal of Molecular Diagnostics</i> , <b>2020</b> , 22, 652-669	5.1	2
157	The role of the androgen receptor as a driver and mitigator of cellular stress. <i>Journal of Molecular Endocrinology</i> , <b>2020</b> , 65, R19-R33	4.5	2
156	Predicting long-term results with circulating tumor cells in patients with de novo androgen sensitive prostate cancer treated with hTERT peptides vaccine.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 98-98	2.2	
155	Investigating Radiotherapy Response in a Novel Syngeneic Model of Prostate Cancer. <i>Cancers</i> , <b>2020</b> , 12,	6.6	2
154	miR-191 promotes radiation resistance of prostate cancer through interaction with RXRA. <i>Cancer Letters</i> , <b>2020</b> , 473, 107-117	9.9	16
153	Methodology for the at-home collection of urine samples for prostate cancer detection. <i>BioTechniques</i> , <b>2020</b> , 68, 65-71	2.5	4
152	Inhibition of O-GlcNAc transferase activates tumor-suppressor gene expression in tamoxifen-resistant breast cancer cells. <i>Scientific Reports</i> , <b>2020</b> , 10, 16992	4.9	7
151	Identification and Validation of Leucine-rich E2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification. <i>European Urology Open Science</i> , <b>2020</b> , 21, 51-60	6.9	6

150	Clinical and functional characterization of CXCR1/CXCR2 biology in the relapse and radiotherapy resistance of primary PTEN-deficient prostate carcinoma. <i>NAR Cancer</i> , <b>2020</b> , 2, zcaa012	5.2	1
149	Human-Based Exposure Levels of Perfluoroalkyl Acids May Induce Harmful Effects to Health by Disrupting Major Components of Androgen Receptor Signalling In Vitro. <i>Exposure and Health</i> , <b>2020</b> , 12, 527-538	8.8	3
148	The Oncogene Metadherin Interacts with the Known Splicing Proteins YTHDC1, Sam68 and T-STAR and Plays a Novel Role in Alternative mRNA Splicing. <i>Cancers</i> , <b>2019</b> , 11,	6.6	17
147	The $\beta$ Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells. <i>Molecular Cancer Research</i> , <b>2019</b> , 17, 2154-2168	6.6	16
146	Human blood-based exposure levels of persistent organic pollutant (POP) mixtures antagonise androgen receptor transactivation and translocation. <i>Environment International</i> , <b>2019</b> , 132, 105083	12.9	9
145	Drivers of AR indifferent anti-androgen resistance in prostate cancer cells. <i>Scientific Reports</i> , <b>2019</b> , 9, 13786	4.9	24
144	IRE1 $\beta$ BP1s pathway promotes prostate cancer by activating c-MYC signaling. <i>Nature Communications</i> , <b>2019</b> , 10, 323	17.4	93
143	CDK9 Inhibition Induces a Metabolic Switch that Renders Prostate Cancer Cells Dependent on Fatty Acid Oxidation. <i>Neoplasia</i> , <b>2019</b> , 21, 713-720	6.4	12
142	High OGT activity is essential for MYC-driven proliferation of prostate cancer cells. <i>Theranostics</i> , <b>2019</b> , 9, 2183-2197	12.1	31
141	A Four-Group Urine Risk Classifier for Predicting Outcome in Prostate Cancer Patients. <i>BJU International</i> , <b>2019</b> , 124, 609	5.6	17
140	The induction of core pluripotency master regulators in cancers defines poor clinical outcomes and treatment resistance. <i>Oncogene</i> , <b>2019</b> , 38, 4412-4424	9.2	33
139	Low Expression of miR-424-3p is Highly Correlated with Clinical Failure in Prostate Cancer. <i>Scientific Reports</i> , <b>2019</b> , 9, 10662	4.9	22
138	A genetic risk score to personalize prostate cancer screening, applied to population data.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 181-181	2.2	1
137	A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer. <i>Oncogene</i> , <b>2019</b> , 38, 1136-1150	9.2	12
136	The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic Mutant Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2018</b> , 17, 1280-1290	6.1	10
135	Cardioprotective effects of dietary rapamycin on adult female C57BLKS/J-Lepr mice. <i>Annals of the New York Academy of Sciences</i> , <b>2018</b> , 1418, 106-117	6.5	10
134	Identification of shared genetic variants between schizophrenia and lung cancer. <i>Scientific Reports</i> , <b>2018</b> , 8, 674	4.9	21
133	Genetics of lipid metabolism in prostate cancer. <i>Nature Genetics</i> , <b>2018</b> , 50, 169-171	36.3	15

132	Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. <i>BMJ, The</i> , <b>2018</b> , 360, j5757	5.9	85
131	A gene signature associated with PTEN activation defines good prognosis intermediate risk prostate cancer cases. <i>Journal of Pathology: Clinical Research</i> , <b>2018</b> , 4, 103-113	5.3	7
130	Genome-wide analysis of AR binding and comparison with transcript expression in primary human fetal prostate fibroblasts and cancer associated fibroblasts. <i>Molecular and Cellular Endocrinology</i> , <b>2018</b> , 471, 1-14	4.4	25
129	Bromodomain-containing proteins in prostate cancer. <i>Molecular and Cellular Endocrinology</i> , <b>2018</b> , 462, 31-40	4.4	17
128	Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy. <i>Annals of Oncology</i> , <b>2018</b> , 29, 215-222	10.3	27
127	Time-varying analysis of electrodermal activity during exercise. <i>PLoS ONE</i> , <b>2018</b> , 13, e0198328	3.7	21
126	Genetic factors influencing prostate cancer risk in Norwegian men. <i>Prostate</i> , <b>2018</b> , 78, 186-192	4.2	9
125	DDIS-16. ONC201 IN COMBINATION WITH RADIATION EXHIBITS SYNERGISTIC EFFICACY IN HIGH GRADE GLIOMAS AND OTHER ADVANCED CANCERS. <i>Neuro-Oncology</i> , <b>2018</b> , 20, vi72-vi72	1	1
124	Prenatal screening for Down syndrome in twin pregnancies: Estimates of screening performance based on 61 affected and 7302 unaffected twin pregnancies. <i>Prenatal Diagnosis</i> , <b>2018</b> , 38, 1079-1085	3.2	4
123	Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer. <i>European Journal of Medicinal Chemistry</i> , <b>2018</b> , 160, 108-119	6.8	24
122	The impact of transcription on metabolism in prostate and breast cancers. <i>Endocrine-Related Cancer</i> , <b>2018</b> , 25, R435-R452	5.7	5
121	The importance of DNA methylation in prostate cancer development. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , <b>2017</b> , 166, 1-15	5.1	85
120	Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology. <i>European Urology</i> , <b>2017</b> , 72, 509-518	10.2	14
119	c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks. <i>EBioMedicine</i> , <b>2017</b> , 18, 83-93	8.8	63
118	Association of maternal serum PAPP-A levels, nuchal translucency and crown-rump length in first trimester with adverse pregnancy outcomes: retrospective cohort study. <i>Prenatal Diagnosis</i> , <b>2017</b> , 37, 705-711	3.2	4
117	Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. <i>Cell Reports</i> , <b>2017</b> , 19, 2045-2059	10.6	72
116	Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer. <i>BMC Genomics</i> , <b>2017</b> , 18, 270	4.5	22
115	Mining Human Prostate Cancer Datasets: The "camcAPP" Shiny App. <i>EBioMedicine</i> , <b>2017</b> , 17, 5-6	8.8	20

114	Dual transcriptome of the immediate neutrophil and <i>Candida albicans</i> interplay. <i>BMC Genomics</i> , <b>2017</b> , 18, 696	4.5	27
113	Lipid degradation promotes prostate cancer cell survival. <i>Oncotarget</i> , <b>2017</b> , 8, 38264-38275	3.3	41
112	Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. <i>Nature Communications</i> , <b>2017</b> , 8, 374	17.4	99
111	The cancer-associated cell migration protein TSPAN1 is under control of androgens and its upregulation increases prostate cancer cell migration. <i>Scientific Reports</i> , <b>2017</b> , 7, 5249	4.9	21
110	Calcium Channel Blocker Use and Risk of Prostate Cancer by TMPRSS2:ERG Gene Fusion Status. <i>Prostate</i> , <b>2017</b> , 77, 282-290	4.2	13
109	Cell cycle-coupled expansion of AR activity promotes cancer progression. <i>Oncogene</i> , <b>2017</b> , 36, 1655-1668	8.2	26
108	Pleiotropic Analysis of Lung Cancer and Blood Triglycerides. <i>Journal of the National Cancer Institute</i> , <b>2016</b> , 108,	9.7	9
107	CTCF modulates Estrogen Receptor function through specific chromatin and nuclear matrix interactions. <i>Nucleic Acids Research</i> , <b>2016</b> , 44, 10588-10602	20.1	29
106	Changes of 5-hydroxymethylcytosine distribution during myeloid and lymphoid differentiation of CD34+ cells. <i>Epigenetics and Chromatin</i> , <b>2016</b> , 9, 21	5.8	15
105	Mapping Protein-DNA Interactions Using ChIP-exo and Illumina-Based Sequencing. <i>Methods in Molecular Biology</i> , <b>2016</b> , 1443, 119-37	1.4	4
104	Using the fluorescent properties of STO-609 as a tool to assist structure-function analyses of recombinant CaMKK2. <i>Biochemical and Biophysical Research Communications</i> , <b>2016</b> , 476, 102-7	3.4	2
103	Glycosylation is an Androgen-Regulated Process Essential for Prostate Cancer Cell Viability. <i>EBioMedicine</i> , <b>2016</b> , 8, 103-116	8.8	46
102	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , <b>2016</b> , 12, 1-222	10.2	3838
101	Gene regulatory mechanisms underpinning prostate cancer susceptibility. <i>Nature Genetics</i> , <b>2016</b> , 48, 387-97	36.3	72
100	Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target. <i>Journal of the National Cancer Institute</i> , <b>2016</b> , 108,	9.7	27
99	The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer. <i>European Urology</i> , <b>2016</b> , 70, 214-8	10.2	47
98	Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study. <i>PLoS Medicine</i> , <b>2016</b> , 13, e1002162	11.6	78
97	HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 74734-74746	3.3	31

96	Inhibition of O-GlcNAc transferase activity reprograms prostate cancer cell metabolism. <i>Oncotarget</i> , <b>2016</b> , 7, 12464-76	3.3	46
95	The role of glycans in the development and progression of prostate cancer. <i>Nature Reviews Urology</i> , <b>2016</b> , 13, 324-33	5.5	53
94	Data for the co-expression and purification of human recombinant CaMKK2 in complex with calmodulin in Escherichia coli. <i>Data in Brief</i> , <b>2016</b> , 8, 733-40	1.2	2
93	Salt-inducible kinase 2 regulates mitotic progression and transcription in prostate cancer. <i>Molecular Cancer Research</i> , <b>2015</b> , 13, 620-635	6.6	31
92	Glucocorticoid receptor and Klf4 co-regulate anti-inflammatory genes in keratinocytes. <i>Molecular and Cellular Endocrinology</i> , <b>2015</b> , 412, 281-9	4.4	24
91	Autophagic bulk sequestration of cytosolic cargo is independent of LC3, but requires GABARAPs. <i>Experimental Cell Research</i> , <b>2015</b> , 333, 21-38	4.2	55
90	Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study. <i>EBioMedicine</i> , <b>2015</b> , 2, 1133-44	8.8	143
89	A differential protein solubility approach for the depletion of highly abundant proteins in plasma using ammonium sulfate. <i>Analyst, The</i> , <b>2015</b> , 140, 8109-17	5	16
88	Divergent androgen regulation of unfolded protein response pathways drives prostate cancer. <i>EMBO Molecular Medicine</i> , <b>2015</b> , 7, 788-801	12	55
87	Slug-dependent upregulation of L1CAM is responsible for the increased invasion potential of pancreatic cancer cells following long-term 5-FU treatment. <i>PLoS ONE</i> , <b>2015</b> , 10, e0123684	3.7	27
86	Genetic Sharing with Cardiovascular Disease Risk Factors and Diabetes Reveals Novel Bone Mineral Density Loci. <i>PLoS ONE</i> , <b>2015</b> , 10, e0144531	3.7	12
85	The androgen receptor controls expression of the cancer-associated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer. <i>Oncotarget</i> , <b>2015</b> , 6, 34358-74	3.3	49
84	Macroautophagic cargo sequestration assays. <i>Methods</i> , <b>2015</b> , 75, 25-36	4.6	21
83	UAP1 is overexpressed in prostate cancer and is protective against inhibitors of N-linked glycosylation. <i>Oncogene</i> , <b>2015</b> , 34, 3744-50	9.2	65
82	Abundant genetic overlap between blood lipids and immune-mediated diseases indicates shared molecular genetic mechanisms. <i>PLoS ONE</i> , <b>2015</b> , 10, e0123057	3.7	30
81	Myc-dependent purine biosynthesis affects nucleolar stress and therapy response in prostate cancer. <i>Oncotarget</i> , <b>2015</b> , 6, 12587-602	3.3	42
80	Studying N-linked glycosylation of receptor tyrosine kinases. <i>Methods in Molecular Biology</i> , <b>2015</b> , 1233, 103-9	1.4	3
79	First trimester maternal serum alpha-fetoprotein is not raised in pregnancies with open spina bifida. <i>Prenatal Diagnosis</i> , <b>2014</b> , 34, 168-71	3.2	10



78	HOXB13, RFX6 and prostate cancer risk. <i>Nature Genetics</i> , <b>2014</b> , 46, 94-5	36.3	5
77	Nuclear ARRB1 induces pseudohypoxia and cellular metabolism reprogramming in prostate cancer. <i>EMBO Journal</i> , <b>2014</b> , 33, 1365-82	13	48
76	Androgen-regulated metabolism and biosynthesis in prostate cancer. <i>Endocrine-Related Cancer</i> , <b>2014</b> , 21, T57-66	5.7	44
75	Maintaining and reprogramming genomic androgen receptor activity in prostate cancer. <i>Nature Reviews Cancer</i> , <b>2014</b> , 14, 187-98	31.3	111
74	The molecular signature of the stroma response in prostate cancer-induced osteoblastic bone metastasis highlights expansion of hematopoietic and prostate epithelial stem cell niches. <i>PLoS ONE</i> , <b>2014</b> , 9, e114530	3.7	31
73	Shared common variants in prostate cancer and blood lipids. <i>International Journal of Epidemiology</i> , <b>2014</b> , 43, 1205-14	7.8	39
72	Endosomal signaling and oncogenesis. <i>Methods in Enzymology</i> , <b>2014</b> , 535, 179-200	1.7	6
71	The impact of HIV infection and antiretroviral therapy on the predicted risk of Down syndrome. <i>Prenatal Diagnosis</i> , <b>2014</b> , 34, 121-7	3.2	5
70	First trimester detection of trisomy 16 using combined biochemical and ultrasound screening. <i>Prenatal Diagnosis</i> , <b>2014</b> , 34, 291-5	3.2	10
69	HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network. <i>EMBO Molecular Medicine</i> , <b>2014</b> , 6, 651-61	12	45
68	The ETS family member GABP $\beta$ modulates androgen receptor signalling and mediates an aggressive phenotype in prostate cancer. <i>Nucleic Acids Research</i> , <b>2014</b> , 42, 6256-69	20.1	26
67	Meta-analysis of prostate cancer gene expression data identifies a novel discriminatory signature enriched for glycosylating enzymes. <i>BMC Medical Genomics</i> , <b>2014</b> , 7, 513	3.7	26
66	The mitochondrial and autosomal mutation landscapes of prostate cancer. <i>European Urology</i> , <b>2013</b> , 63, 702-8	10.2	80
65	Disseminated tumor cells and their prognostic significance in nonmetastatic prostate cancer patients. <i>International Journal of Cancer</i> , <b>2013</b> , 133, 149-55	7.5	30
64	Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. <i>European Urology</i> , <b>2013</b> , 63, 347-53	10.2	115
63	The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. <i>Cancer Cell</i> , <b>2013</b> , 23, 35-47	24.3	282
62	O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells. <i>Cancer Research</i> , <b>2013</b> , 73, 5277-87	10.1	191
61	Modulation of intracellular calcium homeostasis blocks autophagosome formation. <i>Autophagy</i> , <b>2013</b> , 9, 1475-90	10.2	70



60	N-linked glycosylation supports cross-talk between receptor tyrosine kinases and androgen receptor. <i>PLoS ONE</i> , <b>2013</b> , 8, e65016	3.7	35
59	The Effect of AR Overexpression on Androgen Signaling in Prostate Cancer <b>2013</b> , 187-200		0
58	Chromatin binding by the androgen receptor in prostate cancer. <i>Molecular and Cellular Endocrinology</i> , <b>2012</b> , 360, 44-51	4.4	16
57	ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth. <i>Journal of Clinical Investigation</i> , <b>2012</b> , 122, 4621-34	15.9	279
56	Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements. <i>Neoplasia</i> , <b>2012</b> , 14, 600-11	6.4	52
55	Nuclear translocation and functions of growth factor receptors. <i>Seminars in Cell and Developmental Biology</i> , <b>2012</b> , 23, 165-71	7.5	11
54	PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21. <i>American Journal of Pathology</i> , <b>2012</b> , 180, 2097-107	5.8	61
53	Mapping protein-DNA interactions using ChIP-sequencing. <i>Methods in Molecular Biology</i> , <b>2012</b> , 809, 157-73		17
52	Quantitative ELISAs for serum soluble LHCGR and hCG-LHCGR complex: potential diagnostics in first trimester pregnancy screening for stillbirth, Down@ syndrome, preterm delivery and preeclampsia. <i>Reproductive Biology and Endocrinology</i> , <b>2012</b> , 10, 113	5	15
51	Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. <i>EMBO Journal</i> , <b>2012</b> , 31, 1617-1617	13	1
50	Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 11252-7	11.5	82
49	Principles for the post-GWAS functional characterization of cancer risk loci. <i>Nature Genetics</i> , <b>2011</b> , 43, 513-8	36.3	326
48	The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. <i>EMBO Journal</i> , <b>2011</b> , 30, 2719-33	13	423
47	Novel role of androgens in mitochondrial fission and apoptosis. <i>Molecular Cancer Research</i> , <b>2011</b> , 9, 1067-77	6.7	32
46	Global identification of androgen response elements. <i>Methods in Molecular Biology</i> , <b>2011</b> , 776, 255-73	1.4	13
45	Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. <i>EMBO Journal</i> , <b>2011</b> , 30, 3019-27	13	203
44	Principles for the post-GWAS functional characterisation of risk loci. <i>Nature Precedings</i> , <b>2010</b> ,		1
43	Taking risks with translational research. <i>Science Translational Medicine</i> , <b>2010</b> , 2, 24cm10	17.5	2

42	Tumor necrosis factor receptor expression and signaling in renal cell carcinoma. <i>American Journal of Pathology</i> , <b>2010</b> , 177, 943-54	5.8	50
41	Thiol isomerases negatively regulate the cellular shedding activity of ADAM17. <i>Biochemical Journal</i> , <b>2010</b> , 428, 439-50	3.8	135
40	Elevated NCOR1 disrupts a network of dietary-sensing nuclear receptors in bladder cancer cells. <i>Carcinogenesis</i> , <b>2009</b> , 30, 449-56	4.6	37
39	LYRIC/AEG-1 is targeted to different subcellular compartments by ubiquitinylation and intrinsic nuclear localization signals. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 3003-13	12.9	67
38	Putting chromatin immunoprecipitation into context. <i>Journal of Cellular Biochemistry</i> , <b>2009</b> , 107, 19-29	4.7	10
37	Nuclear trafficking and functions of endocytic proteins implicated in oncogenesis. <i>Traffic</i> , <b>2009</b> , 10, 1209-20	3.7	17
36	Chromatin immunoprecipitation (ChIP) methodology and readouts. <i>Methods in Molecular Biology</i> , <b>2009</b> , 505, 123-37	1.4	10
35	ChIPping away at gene regulation. <i>EMBO Reports</i> , <b>2008</b> , 9, 337-43	6.5	61
34	Terminal and progenitor lineage-survival oncogenes as cancer markers. <i>Trends in Molecular Medicine</i> , <b>2008</b> , 14, 486-94	11.5	6
33	EVALUATION OF THE SENSITIVITY OF URETHRAL PRESSURE REFLECTOMETRY (UPR) AND URETHRAL PRESSURE PROFILOMETRY (UPP) TO DETECT PHARMACOLOGICAL AUGMENTATION OF URETHRAL PRESSURE, USING [S,S]-REBOXETINE. <i>Journal of Urology</i> , <b>2008</b> , 179, 521-522	2.5	6
32	A PHASE 2, 8-WEEK, MULTI-CENTER, RANDOMIZED DOUBLE- BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY EVALUATING THE EFFICACY, TOLERABILITY AND SAFETY OF [S,S] - REBOXETINE (PNU-165442G) FOR STRESS URINARY INCONTINENCE IN WOMEN. <i>Journal of Urology</i> , <b>2008</b> , 179, 569-570	2.5	8
31	Structural basis for the nuclear import of the human androgen receptor. <i>Journal of Cell Science</i> , <b>2008</b> , 121, 957-68	5.3	164
30	AURKA overexpression accompanies dysregulation of DNA-damage response genes in invasive urothelial cell carcinoma. <i>Cell Cycle</i> , <b>2008</b> , 7, 3525-33	4.7	11
29	Solitary and repetitive binding motifs for the AP2 complex alpha-appendage in amphiphysin and other accessory proteins. <i>Journal of Biological Chemistry</i> , <b>2008</b> , 283, 5099-109	5.4	19
28	Pro-neural transcription factors as cancer markers. <i>BMC Medical Genomics</i> , <b>2008</b> , 1, 17	3.7	24
27	Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer. <i>Prostate</i> , <b>2008</b> , 68, 661-74	4.2	46
26	Alterations in beta-catenin expression and localization in prostate cancer. <i>Prostate</i> , <b>2008</b> , 68, 1196-205	4.2	61
25	Clathrin is spindle-associated but not essential for mitosis. <i>PLoS ONE</i> , <b>2008</b> , 3, e3115	3.7	8

24	A role for neurotensin in bicalutamide resistant prostate cancer cells. <i>Prostate</i> , <b>2007</b> , 67, 190-202	4.2	25
23	New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. <i>EMBO Reports</i> , <b>2007</b> , 8, 871-8	6.5	219
22	A new look towards BAC-based array CGH through a comprehensive comparison with oligo-based array CGH. <i>BMC Genomics</i> , <b>2007</b> , 8, 84	4.5	36
21	The interplay between clathrin-coated vesicles and cell signalling. <i>Seminars in Cell and Developmental Biology</i> , <b>2007</b> , 18, 459-70	7.5	39
20	In Vitro Techniques <b>2006</b> , 201-378		
19	Role of the AP2 beta-appendage hub in recruiting partners for clathrin-coated vesicle assembly. <i>PLoS Biology</i> , <b>2006</b> , 4, e262	9.7	197
18	The developing role of receptors and adaptors. <i>Nature Reviews Cancer</i> , <b>2006</b> , 6, 403-9	31.3	76
17	Huntingtin interacting protein 1 modulates the transcriptional activity of nuclear hormone receptors. <i>Journal of Cell Biology</i> , <b>2005</b> , 170, 191-200	7.3	59
16	Evolving nature of the AP2 alpha-appendage hub during clathrin-coated vesicle endocytosis. <i>EMBO Journal</i> , <b>2004</b> , 23, 4371-83	13	154
15	COP and clathrin-coated vesicle budding: different pathways, common approaches. <i>Current Opinion in Cell Biology</i> , <b>2004</b> , 16, 379-91	9	240
14	BAR domains as sensors of membrane curvature: the amphiphysin BAR structure. <i>Science</i> , <b>2004</b> , 303, 495-9	33.3	1353
13	Clathrin adaptor epsinR is required for retrograde sorting on early endosomal membranes. <i>Developmental Cell</i> , <b>2004</b> , 6, 525-38	10.2	191
12	EpsinR: an AP1/clathrin interacting protein involved in vesicle trafficking. <i>Journal of Cell Biology</i> , <b>2003</b> , 160, 213-22	7.3	206
11	Curvature of clathrin-coated pits driven by epsin. <i>Nature</i> , <b>2002</b> , 419, 361-6	50.4	798
10	GTPase activity of dynamin and resulting conformation change are essential for endocytosis. <i>Nature</i> , <b>2001</b> , 410, 231-5	50.4	378
9	Endosomal localization and receptor dynamics determine tyrosine phosphorylation of hepatocyte growth factor-regulated tyrosine kinase substrate. <i>Molecular and Cellular Biology</i> , <b>2000</b> , 20, 7685-92	4.8	110
8	Regulation of endosome fusion. <i>Molecular Membrane Biology</i> , <b>1999</b> , 16, 73-9	3.4	48
7	Involvement of the endosomal autoantigen EEA1 in homotypic fusion of early endosomes. <i>Current Biology</i> , <b>1998</b> , 8, 881-4	6.3	189

6	Inhibition of endosome fusion by wortmannin persists in the presence of activated Rab5. <i>Molecular Biology of the Cell</i> , <b>1998</b> , 9, 323-32	3.5	46
5	Localization of polymorphic N-acetyltransferase (NAT2) in tissues of inbred mice. <i>Pharmacogenetics and Genomics</i> , <b>1997</b> , 7, 121-30		74
4	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations		1
3	African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer		1
2	The spatial landscape of clonal somatic mutations in benign and malignant tissue		1
1	Single-cell ATAC and RNA sequencing reveal pre-existing and persistent subpopulations of cells associated with relapse of prostate cancer		1